Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):691-697. doi: 10.31557/APJCP.2021.22.3.691.
Seizure is commonly found in patients with glioma. This study aimed to find risk factors for seizures in Indonesian patients with glioma. We also sought to determine the association between seizure and survival in this patient population.
Patients with glioma were enrolled from the Dr. Sardjito General Hospital and other hospitals in Yogyakarta Province, Indonesia. Detailed demographic and clinical data were collected from medical records. DNA extraction and polymerase chain reaction (PCR) were performed to detect IDH1 mutation. Tumor tissue samples were stained by hematoxylin-eosin and classified according to the 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumors. Expression of Ki-67 was detected by immunohistochemistry staining. Survival data were also collected.
In total, 107 patients were included in the analysis. Age, gender, history of smoking, tumor side, tumor grade, Ki-67 expression, and IDH1 mutation were not associated with seizure. Tumors involving the frontal lobe (p=0.037) and oligodendroglioma histology (p=0.031) were associated with the development of seizures in this study. However, multivariate analysis showed that only oligodendrogial histology was associated with seizure [p=0.032, odds ratio (OR) = 4.77, 95% confidence interval (CI) = 1.146-19.822]. Patients with seizures have significantly longer median overall survival than patients without seizures (69.3±25.01 vs. 10.6±6.14 months, respectively, p=0.04).
This study showed that seizure in patients with glioma in Indonesia is associated with frontal lobe location and oligodendroglioma histology. Patients with seizures also have significantly longer overall survival.
.
癫痫在脑胶质瘤患者中较为常见。本研究旨在寻找印度尼西亚脑胶质瘤患者癫痫发作的危险因素。我们还试图确定癫痫发作与该患者人群的生存之间的关系。
从印度尼西亚日惹省的 Sardjito 综合医院和其他医院招募脑胶质瘤患者。从病历中收集详细的人口统计学和临床数据。进行 DNA 提取和聚合酶链反应(PCR)以检测 IDH1 突变。对肿瘤组织样本进行苏木精-伊红染色,并根据 2016 年世界卫生组织(WHO)中枢神经系统(CNS)肿瘤分类进行分类。通过免疫组织化学染色检测 Ki-67 的表达。还收集了生存数据。
共有 107 例患者纳入分析。年龄、性别、吸烟史、肿瘤侧、肿瘤分级、Ki-67 表达和 IDH1 突变与癫痫发作无关。额叶受累(p=0.037)和少突胶质细胞瘤组织学(p=0.031)与本研究中癫痫发作的发展相关。然而,多变量分析显示只有少突胶质细胞瘤组织学与癫痫发作相关[p=0.032,优势比(OR)=4.77,95%置信区间(CI)=1.146-19.822]。有癫痫发作的患者的中位总生存期明显长于无癫痫发作的患者(69.3±25.01 与 10.6±6.14 个月,分别,p=0.04)。
本研究表明,印度尼西亚脑胶质瘤患者的癫痫发作与额叶位置和少突胶质细胞瘤组织学有关。有癫痫发作的患者的总生存期也明显更长。